Search

Displaying results 3031 - 3040 of 10000 in total
  1. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.

  2. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  3. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), in both adult and pediatric patients whose disease has not responded to or … [A2331] Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in the inhibition of DNA synthesis and cytotoxicity.

  4. Drug

    Ropivacaine

    go.drugbank.com/drugs/DB00296
    ApprovedInvestigational

    It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.[L42140]

    Synonyms: L-N-n-propylpipecolic acid-2,6-xylidideProducts: ROVANAEST 2.0 (Ropivacaine Hydrochloride 2mg/mL Solution for Injection or Infusion USP), ROVANAEST 7.5 (Ropivacaine Hydrochloride 7.5mg/mL Solution for Injection or Infusion USP)
  5. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    Zilganersen is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide used to treat Alexander disease. … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  6. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    Sulopenem etzadroxil is a prodrug of the penem antibacterial [sulopenem]. Like other beta-lactam antibacterials, it is a time-dependent inhibitor of bacterial cell wall synthesis. … [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

  7. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.

  8. Drug

    C11-12 isoparaffin

    go.drugbank.com/drugs/DB11329
    Approved

    C11-12 isoparaffin is a mixture of branched chain hydrocarbons with 11C or 12C's in the alkyl chain. It is found in cosmetic and personal care products as solvents or skin conditioning agent.

  9. Drug

    Iseganan

    go.drugbank.com/drugs/DB16010
    Investigational

    Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).

    Categories: Pore Forming Cytotoxic Proteins
  10. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.